DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4j3hqr/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Aestus Therapeutics, Inc.
- Astellas Pharma Inc.
- Collegium Pharmaceutical, Inc.
- Eisai Co., Ltd.
- Eli Lilly and Company
- Frontier Biotechnologies Co., Ltd
- Grunenthal GmbH
- Ipsen S.A.
- MEDRx Co., Ltd.
- Merck & Co., Inc.
- Mesoblast Limited
- Nektar Therapeutics
- Pacira Pharmaceuticals, Inc.
- Paladin Labs Inc.
- Pfizer Inc.
- Stayble Therapeutics
- Teikoku Pharma USA, Inc.
Drug Profiles
- (acetaminophen + tramadol hydrochloride)
- (diclofenac sodium + eperisone)
- (etodolac + lidocaine)
- (etoricoxib + tizanidine)
- (oxycodone hydrochloride + naltrexone) ER
- AB-001
- abobotulinumtoxin A
- ASP-7962
- Atx09-002
- bupivacaine hydrochloride
- cebranopadol
- Drug for Chronic Low Back Pain
- duloxetine hydrochloride DR
- eperisone SR
- flurbiprofen sodium
- MPC-06ID
- NKTR-181
- oxycodone hydrochloride ER
- PF-06372865
For more information visit http://www.researchandmarkets.com/research/4j3hqr/low_back_pain
